Compare Merck & Co., Inc. (MRK) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Teucrium Wheat Fund — how do they compare? Merck & Co., Inc. trades at $144.69 (market cap $351.28B), while Teucrium Wheat Fund trades at $24.85 (market cap $273.67M). The key difference: Merck & Co., Inc. is far larger — about 1283.6× Teucrium Wheat Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Teucrium Wheat Fund for 40 Days on average.
| MRK | WEAT | |
|---|---|---|
Market Cap | $351.28B | $273.67M |
Volume | 7,969,665 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $156.43 | $28.00 |
52-Week Low | $82.49 | $19.88 |
Typical Hold Time | 98 Days | 40 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
WEAT trades at $24.9, down 2.31% over the past day amid a bearish technical signal from moving averages. The stock's technical indicators show neutral oscillators but selling pressure from the ADX. Recent news highlights WEAT's strong performance earlier in the year, with a 25% year-to-date gain as of July 2026, though inflation concerns persist as a market-wide theme.
The outlook for WEAT is cautious due to bearish technical momentum and macroeconomic headwinds from inflation. Investment opportunity exists if the stock holds key support levels, but risks include continued selling pressure and sensitivity to broader economic conditions. Investors should weigh technical weakness against the fund's earlier 2026 gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
